United States

Tamara Mathias

UnitedHealth boosts earnings forecast, set to pass price discounts to patients

Jul 18 2019

UnitedHealth Group Inc will stick with its decision to pass on drug maker discounts to patients to help them beat rising medicine prices despite the U.S. government having withdrawn a similar proposed policy in its health programs, its top executive said on Thursday.

Male victims of domestic violence struggle to disclose abuse

Jul 17 2019

(Reuters Health) - Men who experience domestic violence and abuse often don't seek help until the problem becomes a crisis, researchers say.

Blue Apron beefs up menu with Beyond Meat, shares surge 35%

Jul 17 2019

(This version of July 16th story corrects headline to show closing stock change)

Electronic consults with allergists save time for doctors and patients

Jul 02 2019

When allergy specialists advise other doctors via "e-consults," everyone - patients included - saves time, a new study suggests.

FDA approves expanded label for Regeneron/Sanofi's Dupixent

Jun 26 2019

The U.S. Food and Drug Administration on Wednesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug Dupixent to treat nasal polyps, marking the third major use for the injectable medicine.

Pfizer makes $10.6 billion cancer bet in cash deal for Array Biopharma

Jun 17 2019

Pfizer Inc said on Monday it would buy Array Biopharma Inc for $10.64 billion in cash, a deal it hopes will help make it a leader in colon cancer and build up its pipeline of oncology drugs.

VBI's shares plunge after hep B vaccine fails secondary goal in late-stage trial

Jun 17 2019

VBI Vaccines Inc said on Monday a late-stage study was unsuccessful in showing two doses of its hepatitis B vaccine were as effective as three doses of an older vaccine from GlaxoSmithKline, sending its shares plunging 66%.

Chewy shares surge 63% in debut as investors bank on booming pet market

Jun 14 2019

Shares of Chewy Inc soared 63% in their public debut, giving the online pet products retailer a market value of $14.35 billion, more than four times the price PetSmart paid for it in 2017. | Video

Bluebird prices gene therapy at 1.58 million euros over 5 years

Jun 14 2019

Bluebird bio Inc on Friday set a price for its gene therapy, Zynteglo, at 1.58 million euros ($1.78 million) over five years, after winning conditional approval in Europe this month to treat a rare genetic blood disorder.

World News